Company Overview: Asterias Biotherapeutics

Industry News

6 Sep

Asterias Biotherapeutics to Present at Upcoming Conferences

FREMONT, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that members of the Company’s management team will be presenting at two upcoming investor conferences in September: Rodman & Renshaw Annual Global Investment Conference on Monday,...

Read more

23 Aug

Asterias Biotherapeutics Opens Additional Clinical Site for AST-OPC1 SCiStar Study

FREMONT, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Washington University School of Medicine in St. Louis, MO, has been added as a clinical site in the company’s ongoing SCiStar Phase 1/2a clinical...

Read more

14 Aug

Asterias Announces Major AST-VAC2 Development Milestone: First cGMP-Compliant Lot Successfully Manufactured to Support First Clinical Study of AST-VAC2

FREMONT, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Cancer Research UK, supported by Asterias technical personnel, has successfully completed manufacture of the first cGMP (current Good Manufacturing Practice) clinical grade lot of...

Read more

9 Aug

Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial

FREMONT, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment and dosing of the first patient in the fifth and final cohort in the company’s ongoing SCiStar Phase 1/2a clinical study of AST-OPC1 in...

Read more

31 Jul

Asterias Biotherapeutics to Report Second Quarter Results on August 14, 2017

FREMONT, Calif., July 31, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release second quarter 2017 financial and operational results on Monday, August 14, 2017 after the close of the U.S. financial...

Read more

17 Jul

Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study’s AIS-A 20 Million Cell Cohort

Twenty patients have been enrolled in SCiStar study 20 million cell dose escalation cohort to inform future trial design Dosing fifth patient in this cohort triggers $1.5 million grant payment FREMONT, Calif., July 17, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced...

Read more

12 Jul

Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study’s AIS-B 10 Million Cell Cohort

First enrolled cohort comprised of patients with motor complete, sensory incomplete paralysis FREMONT, Calif., July 12, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced completion of enrollment and dosing of the AIS-B 10 million cell cohort in the company’s ongoing...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address